Barbara Jean Ottley, MD
Payments from drug & device makers
Across 674 payments — averaging $171.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Biohaven Pharmaceuticals, Inc.$33K
- Biohaven Pharmaceutical Holding Company Ltd.$30K
- Teva Pharmaceuticals USA, Inc.$11K
- Livanova USA, Inc.$2K
- EMD Serono, Inc.$983
- plus $5K from 31 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$97,06084%
- Travel & lodging$7,7777%
- Food & beverage$10,3359%
- Education$2190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $33,110 |
| Biohaven Pharmaceuticals, Inc. | 63 | $32,808 |
| Biohaven Pharmaceutical Holding Company Ltd. | 58 | $30,391 |
| Teva Pharmaceuticals USA, Inc. | 64 | $11,451 |
| Livanova USA, Inc. | 20 | $1,606 |
| EMD Serono, Inc. | 60 | $983 |
| Biogen | 42 | $904 |
| Pfizer | 44 | $573 |
| Sanofi | 29 | $556 |
| Novartis | 20 | $331 |
| Neurocrine Biosciences, Inc. | 18 | $317 |
| Bristol Myers Squibb | 20 | $306 |
| SK Life Science, Inc. | 13 | $254 |
| Amgen | 15 | $249 |
| AstraZeneca | 22 | $241 |
| Kyowa Kirin, Inc. | 8 | $164 |
| Jazz Pharmaceuticals Inc. | 10 | $153 |
| Argenx US, Inc. | 7 | $145 |
| Sumitomo Pharma America, Inc. | 8 | $144 |
| Upsher-smith Laboratories LLC | 9 | $138 |
| Lilly USA, LLC | 9 | $128 |
| Lundbeck LLC | 7 | $111 |
| Acadia Pharmaceuticals Inc | 5 | $104 |
| Eisai Inc. | 5 | $102 |
| Medtronic(2 entities) | 2 | $67 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Corium, LLC | 2 | $35 |
| Avion Pharmaceuticals | 2 | $33 |
| Abbott | 1 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| MDD US Operations, LLC | 1 | $22 |
| Tanabe Pharma America, Inc. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Amylyx Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Neurelis, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$61,746
- UBRELVY$32,442
- AUSTEDO$10,611
- QULIPTA$3,515
- VNS Therapy$876
- TYSABRI$300
How this compares
$115,690 in reported general payments places this provider in the 85th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $194,513 |
| CopaxoneGlatiramer Acetate | 28 | $164,173 |
| NuplazidPimavanserin Tartrate | 24 | $120,731 |
| Teriflunomide | 30 | $42,172 |
| Rasagiline Mesylate | 114 | $24,511 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,646 |
| Levetiracetam | 182 | $7,265 |
| Ropinirole Hcl | 259 | $6,074 |
| SavellaMilnacipran Hcl | 14 | $5,561 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 186 | $5,491 |
| Memantine Hcl | 227 | $4,917 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 17 | $4,626 |
| Sumatriptan | 11 | $4,570 |
| Pramipexole ErPramipexole Di-Hcl | 12 | $3,202 |
| Gabapentin | 177 | $2,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $11,451 | $358,68640 claims |
| Acadia Pharmaceuticals IncNuplazid | $104 | $120,73124 claims |
| PfizerNurtec Odt | $573 | $22,64612 claims |
| AbbVieSavella | $33,110 | $5,56114 claims |
| Upsher-smith Laboratories LLCTopiramate | $138 | $37951 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 131 neurology providers in Kansas.
Other neurology in Hays
- Ivan OsorioKansas City$101.7M
- Sharon LynchKansas City$9.3M
- Jeffrey BurnsKansas City$6.2M
- Rajesh PahwaKansas City$5M
- Jeffrey KaplanLenexa$4.4M
- Mamatha PasnoorKansas City$3.9M
- Vernon RoweShawnee$1.5M
- William MalloneeHutchinson$1.1M
- Constantine FarmakidisKansas City$649K
- Ricky LeeWichita$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.